Q-and-A from FDA addresses guidance on ANDAs

08/29/2013 | In-PharmaTechnologist.com

The FDA has published notes in a question-and-answer format after hearing from drugmakers about its initial stability draft guidance for abbreviated new drug applications. The notes address issues such as the use of accelerated vs. intermediate data and requirements for a drug product's three primary batches.

View Full Article in:

In-PharmaTechnologist.com

Published in Brief: